Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects

European Journal of Pain

Volumn 11, Issue 6, 2007, Pages 599-604

  Fredheim, Olav Magnus S ^a,b   Borchgrevink, Petter C ^a,c   Klepstad, Pål ^a,c   Kaasa, Stein ^a,c   Dale, Ola ^a,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Sandnessjoen Hospital   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chronic pain; Methadone; Morphine; Opioid switch; Pharmacokinetic

Indexed keywords

METHADONE; MORPHINE;

ADULT; AGED; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; FEMALE; HUMAN; LONG TERM CARE; MALE; METHADONE TREATMENT; PILOT STUDY; PRIORITY JOURNAL;

ADULT; AGED; ANALGESICS, OPIOID; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; MORPHINE; PAIN, INTRACTABLE; PILOT PROJECTS; TIME; TREATMENT OUTCOME;

EID: 34249338680     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2006.09.006     Document Type: Article

References (26)

1. Anggard E., Gunne L.M., Homstrand J., McMahon R.E., Sandberg C.G., and Sullivan H.R. Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 17 (1975) 258-266
2. Coffman B.L., Rios G.R., King C.D., and Tephly T.R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25 (1997) 1-4
3. Dale O., Sheffels P., and Kharasch E.D. Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol 58 (2004) 156-162
4. de Stoutz N.D., Bruera E., and Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manag 10 (1995) 378-384
5. de Vos J.W., Geerlings P.J., van den Brink W., Ufkes J.G., and van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 48 (1995) 361-366
6. Eap C.B., Bertschy G., and Baumann P. High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry 55 (1998) 89-90
7. Ferrari A., Coccia C.P.R., Bertolini A., and Sternieri E. Methadone - metabolism, pharmacokinetics and interactions. Pharmacol Res 50 (2004) 551-559
8. Fredheim O., Kaasa S., Dale O., Klepstad P., Landro N., and Borchgrevink P.C. Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine month follow-up study. Palliat Med 20 (2006) 35-41
9. Fredheim O., Borchgrevink P.C., Hegrenæs L., Kaasa S., Dale O., and Klepstad P. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc: a prospective 9 months follow-up study. J Pain Symptom Manag 32 2 (2006) 180-185
10. Garrido M.J., and Troconiz I.F. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J Pharmacol Toxicol 42 (1999) 61-66
11. Gourlay G.K., Cherry D.A., and Cousins M.J. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25 (1986) 297-312
12. Hanks G.W., de Conno F., Cherny N., Hanna M., Kalso E., McQuay H.J., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84 (2001) 587-593
13. Hasselstrom J., and Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 24 (1993) 344-354
14. Holmstrand J., Anggard E., and Gunne L.M. Methadone maintenance: plasma levels and therapeutic outcome. Clin Pharmacol Ther 23 (1978) 175-180
15. Iribarne C., Berthou F., Baird S., Dreano Y., Picart D., Bail J.P., et al. Involvement of cytochrome P450 3A4 enzyme in the N-demetylation of methadone in human liver microsomes. Chem Res Toxicol 9 (1996) 365-373
16. Klepstad P., Dale O., Skorpen F., Borchgrevink P.C., and Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 49 (2005) 902-908
17. Kristensen K., Christensen C.B., and Christrup L.L. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 56 (1995) 45-50
18. Lawlor P.G., Turner K.S., Hanson J., and Bruera E.D. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82 (1998) 1167-1173
19. Lotsch J., Weiss M., Ahne G., Kobal G., and Geisslinger G. Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. Anesthesiology 90 (1999) 1026-1038
20. Lotsch J., Skarke C., Wieting J., Oertel B.G., Schmidt H., Brockmoller J., et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution and drug action. Clin Pharmacol Ther 79 (2006) 72-89
21. Meresaar U., Nilsson M.I., Holmstrand J., and Anggard E. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol 20 (1981) 473-478
22. Projean D., Morin P.E., Tu T.M., and Ducharme J. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demetylation in human liver microsomes. Xenobiotica 33 (2003) 841-854
23. Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 11 (1986) 87-106
24. Verebely B., Volavka J., Mule S., and Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 18 (1975) 180-190
25. Wiffen PJ, Edwards JE, Barden J, McQuay HJ. Oral morphine for cancer pain. The cochrane database of systematic reviews 2003, Issue 4. Art. No.: CD003868. DOI: 10.1002/14651858. CD003868.
26. Wolff K., Sanderson M., Hay A.W.M., and Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem 37 (1991) 205-209